nodes	percent_of_prediction	percent_of_DWPC	metapath
Omeprazole—CYP3A4—bone cancer	0.309	1	CbGaD
Omeprazole—ABCC3—Cisplatin—bone cancer	0.0984	0.201	CbGbCtD
Omeprazole—ABCC3—Doxorubicin—bone cancer	0.0659	0.135	CbGbCtD
Omeprazole—ABCC3—Methotrexate—bone cancer	0.0639	0.13	CbGbCtD
Omeprazole—CYP1B1—Doxorubicin—bone cancer	0.057	0.116	CbGbCtD
Omeprazole—ABCG2—Carboplatin—bone cancer	0.0473	0.0965	CbGbCtD
Omeprazole—ABCG2—Cisplatin—bone cancer	0.0404	0.0825	CbGbCtD
Omeprazole—ABCG2—Doxorubicin—bone cancer	0.0271	0.0553	CbGbCtD
Omeprazole—ABCG2—Methotrexate—bone cancer	0.0262	0.0535	CbGbCtD
Omeprazole—CYP2C9—Cisplatin—bone cancer	0.015	0.0306	CbGbCtD
Omeprazole—ABCB1—Cisplatin—bone cancer	0.0146	0.0297	CbGbCtD
Omeprazole—ABCB1—Doxorubicin—bone cancer	0.00977	0.0199	CbGbCtD
Omeprazole—ABCB1—Methotrexate—bone cancer	0.00946	0.0193	CbGbCtD
Omeprazole—CYP2D6—Doxorubicin—bone cancer	0.0092	0.0188	CbGbCtD
Omeprazole—CYP3A4—Doxorubicin—bone cancer	0.00585	0.0119	CbGbCtD
Omeprazole—Esomeprazole—CYP3A4—bone cancer	0.00125	0.335	CrCbGaD
Omeprazole—Rabeprazole—CYP3A4—bone cancer	0.000904	0.242	CrCbGaD
Omeprazole—Pantoprazole—CYP3A4—bone cancer	0.000904	0.242	CrCbGaD
Omeprazole—Lansoprazole—CYP3A4—bone cancer	0.000674	0.181	CrCbGaD
Omeprazole—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000332	0.00465	CbGpPWpGaD
Omeprazole—CYP2C18—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00033	0.00462	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000325	0.00454	CbGpPWpGaD
Omeprazole—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000322	0.00451	CbGpPWpGaD
Omeprazole—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000319	0.00447	CbGpPWpGaD
Omeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000318	0.00445	CbGpPWpGaD
Omeprazole—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000309	0.00432	CbGpPWpGaD
Omeprazole—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0003	0.0042	CbGpPWpGaD
Omeprazole—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000299	0.00418	CbGpPWpGaD
Omeprazole—CYP1B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000296	0.00414	CbGpPWpGaD
Omeprazole—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000296	0.00414	CbGpPWpGaD
Omeprazole—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000296	0.00414	CbGpPWpGaD
Omeprazole—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000284	0.00397	CbGpPWpGaD
Omeprazole—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000273	0.00382	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000253	0.00354	CbGpPWpGaD
Omeprazole—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000251	0.00351	CbGpPWpGaD
Omeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00025	0.0035	CbGpPWpGaD
Omeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000245	0.00343	CbGpPWpGaD
Omeprazole—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000244	0.00342	CbGpPWpGaD
Omeprazole—CYP1B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000243	0.0034	CbGpPWpGaD
Omeprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000232	0.00325	CbGpPWpGaD
Omeprazole—CYP2C18—Tryptophan metabolism—MDM2—bone cancer	0.000231	0.00324	CbGpPWpGaD
Omeprazole—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000228	0.0032	CbGpPWpGaD
Omeprazole—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000228	0.00319	CbGpPWpGaD
Omeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000217	0.00304	CbGpPWpGaD
Omeprazole—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	0.000208	0.00292	CbGpPWpGaD
Omeprazole—CYP11A1—Biological oxidations—CYP3A4—bone cancer	0.000202	0.00283	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.0002	0.0028	CbGpPWpGaD
Omeprazole—CYP11A1—Metapathway biotransformation—CYP3A4—bone cancer	0.0002	0.0028	CbGpPWpGaD
Omeprazole—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000195	0.00273	CbGpPWpGaD
Omeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000187	0.00262	CbGpPWpGaD
Omeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000186	0.0026	CbGpPWpGaD
Omeprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000185	0.00259	CbGpPWpGaD
Omeprazole—CYP11A1—Corticotropin-releasing hormone—BRAF—bone cancer	0.000183	0.00257	CbGpPWpGaD
Omeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000182	0.00255	CbGpPWpGaD
Omeprazole—CYP2C18—Biological oxidations—CYP3A4—bone cancer	0.000175	0.00245	CbGpPWpGaD
Omeprazole—CYP11A1—Biological oxidations—GSTP1—bone cancer	0.000173	0.00242	CbGpPWpGaD
Omeprazole—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	0.000173	0.00242	CbGpPWpGaD
Omeprazole—CYP11A1—Metapathway biotransformation—GSTP1—bone cancer	0.000171	0.00239	CbGpPWpGaD
Omeprazole—CYP1B1—Tryptophan metabolism—MDM2—bone cancer	0.000171	0.00239	CbGpPWpGaD
Omeprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000169	0.00237	CbGpPWpGaD
Omeprazole—ABCC3—Fluoropyrimidine Activity—TP53—bone cancer	0.000168	0.00236	CbGpPWpGaD
Omeprazole—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000167	0.00234	CbGpPWpGaD
Omeprazole—ABCC3—NRF2 pathway—TGFBR2—bone cancer	0.000166	0.00233	CbGpPWpGaD
Omeprazole—ABCC3—NRF2 pathway—GSTP1—bone cancer	0.000166	0.00233	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000164	0.0023	CbGpPWpGaD
Omeprazole—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00016	0.00224	CbGpPWpGaD
Omeprazole—CYP1B1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000154	0.00215	CbGpPWpGaD
Omeprazole—Neutropenia—Doxorubicin—bone cancer	0.000152	0.0012	CcSEcCtD
Omeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000151	0.00212	CbGpPWpGaD
Omeprazole—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Omeprazole—Hepatitis—Methotrexate—bone cancer	0.00015	0.00119	CcSEcCtD
Omeprazole—Pollakiuria—Doxorubicin—bone cancer	0.00015	0.00119	CcSEcCtD
Omeprazole—CYP2C18—Biological oxidations—GSTP1—bone cancer	0.00015	0.0021	CbGpPWpGaD
Omeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00015	0.0021	CbGpPWpGaD
Omeprazole—Haematuria—Epirubicin—bone cancer	0.000149	0.00118	CcSEcCtD
Omeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000149	0.00209	CbGpPWpGaD
Omeprazole—Pharyngitis—Methotrexate—bone cancer	0.000149	0.00118	CcSEcCtD
Omeprazole—Urinary tract disorder—Methotrexate—bone cancer	0.000148	0.00118	CcSEcCtD
Omeprazole—Photosensitivity reaction—Doxorubicin—bone cancer	0.000148	0.00118	CcSEcCtD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000148	0.00207	CbGpPWpGaD
Omeprazole—Hepatobiliary disease—Epirubicin—bone cancer	0.000148	0.00117	CcSEcCtD
Omeprazole—Weight increased—Doxorubicin—bone cancer	0.000148	0.00117	CcSEcCtD
Omeprazole—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	0.000148	0.00207	CbGpPWpGaD
Omeprazole—Epistaxis—Epirubicin—bone cancer	0.000148	0.00117	CcSEcCtD
Omeprazole—Urethral disorder—Methotrexate—bone cancer	0.000147	0.00117	CcSEcCtD
Omeprazole—Weight decreased—Doxorubicin—bone cancer	0.000147	0.00116	CcSEcCtD
Omeprazole—Sinusitis—Epirubicin—bone cancer	0.000147	0.00116	CcSEcCtD
Omeprazole—Agranulocytosis—Epirubicin—bone cancer	0.000146	0.00116	CcSEcCtD
Omeprazole—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000146	0.00204	CbGpPWpGaD
Omeprazole—Infestation NOS—Doxorubicin—bone cancer	0.000145	0.00115	CcSEcCtD
Omeprazole—Infestation—Doxorubicin—bone cancer	0.000145	0.00115	CcSEcCtD
Omeprazole—Visual impairment—Methotrexate—bone cancer	0.000145	0.00115	CcSEcCtD
Omeprazole—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000144	0.00114	CcSEcCtD
Omeprazole—Hypersensitivity—Cisplatin—bone cancer	0.000143	0.00114	CcSEcCtD
Omeprazole—Bradycardia—Epirubicin—bone cancer	0.000143	0.00113	CcSEcCtD
Omeprazole—Renal failure—Doxorubicin—bone cancer	0.000142	0.00113	CcSEcCtD
Omeprazole—Erythema multiforme—Methotrexate—bone cancer	0.000142	0.00113	CcSEcCtD
Omeprazole—Stomatitis—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Omeprazole—Jaundice—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Omeprazole—Rhinitis—Epirubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Omeprazole—Urinary tract infection—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Omeprazole—Conjunctivitis—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Omeprazole—Hepatitis—Epirubicin—bone cancer	0.00014	0.00111	CcSEcCtD
Omeprazole—Eye disorder—Methotrexate—bone cancer	0.00014	0.00111	CcSEcCtD
Omeprazole—Tinnitus—Methotrexate—bone cancer	0.00014	0.00111	CcSEcCtD
Omeprazole—Hypoaesthesia—Epirubicin—bone cancer	0.00014	0.00111	CcSEcCtD
Omeprazole—Asthenia—Cisplatin—bone cancer	0.000139	0.00111	CcSEcCtD
Omeprazole—Pharyngitis—Epirubicin—bone cancer	0.000139	0.00111	CcSEcCtD
Omeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000139	0.00195	CbGpPWpGaD
Omeprazole—Urinary tract disorder—Epirubicin—bone cancer	0.000139	0.0011	CcSEcCtD
Omeprazole—Oedema peripheral—Epirubicin—bone cancer	0.000138	0.0011	CcSEcCtD
Omeprazole—Haematuria—Doxorubicin—bone cancer	0.000138	0.00109	CcSEcCtD
Omeprazole—Connective tissue disorder—Epirubicin—bone cancer	0.000138	0.00109	CcSEcCtD
Omeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000138	0.00193	CbGpPWpGaD
Omeprazole—Urethral disorder—Epirubicin—bone cancer	0.000138	0.00109	CcSEcCtD
Omeprazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000137	0.00192	CbGpPWpGaD
Omeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000137	0.00192	CbGpPWpGaD
Omeprazole—Hepatobiliary disease—Doxorubicin—bone cancer	0.000137	0.00109	CcSEcCtD
Omeprazole—Epistaxis—Doxorubicin—bone cancer	0.000137	0.00108	CcSEcCtD
Omeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000136	0.0019	CbGpPWpGaD
Omeprazole—Sinusitis—Doxorubicin—bone cancer	0.000136	0.00108	CcSEcCtD
Omeprazole—Immune system disorder—Methotrexate—bone cancer	0.000136	0.00108	CcSEcCtD
Omeprazole—Visual impairment—Epirubicin—bone cancer	0.000135	0.00107	CcSEcCtD
Omeprazole—Mediastinal disorder—Methotrexate—bone cancer	0.000135	0.00107	CcSEcCtD
Omeprazole—Agranulocytosis—Doxorubicin—bone cancer	0.000135	0.00107	CcSEcCtD
Omeprazole—Chills—Methotrexate—bone cancer	0.000135	0.00107	CcSEcCtD
Omeprazole—Diarrhoea—Cisplatin—bone cancer	0.000133	0.00105	CcSEcCtD
Omeprazole—Erythema multiforme—Epirubicin—bone cancer	0.000133	0.00105	CcSEcCtD
Omeprazole—Alopecia—Methotrexate—bone cancer	0.000133	0.00105	CcSEcCtD
Omeprazole—Bradycardia—Doxorubicin—bone cancer	0.000132	0.00105	CcSEcCtD
Omeprazole—Mental disorder—Methotrexate—bone cancer	0.000132	0.00104	CcSEcCtD
Omeprazole—Eye disorder—Epirubicin—bone cancer	0.000131	0.00104	CcSEcCtD
Omeprazole—Tinnitus—Epirubicin—bone cancer	0.000131	0.00104	CcSEcCtD
Omeprazole—Malnutrition—Methotrexate—bone cancer	0.000131	0.00104	CcSEcCtD
Omeprazole—ABCC3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000131	0.00183	CbGpPWpGaD
Omeprazole—Flushing—Epirubicin—bone cancer	0.00013	0.00103	CcSEcCtD
Omeprazole—Rhinitis—Doxorubicin—bone cancer	0.00013	0.00103	CcSEcCtD
Omeprazole—Hepatitis—Doxorubicin—bone cancer	0.00013	0.00103	CcSEcCtD
Omeprazole—Hypoaesthesia—Doxorubicin—bone cancer	0.000129	0.00103	CcSEcCtD
Omeprazole—CYP1B1—Biological oxidations—CYP3A4—bone cancer	0.000129	0.00181	CbGpPWpGaD
Omeprazole—Pharyngitis—Doxorubicin—bone cancer	0.000129	0.00102	CcSEcCtD
Omeprazole—Urinary tract disorder—Doxorubicin—bone cancer	0.000128	0.00102	CcSEcCtD
Omeprazole—Oedema peripheral—Doxorubicin—bone cancer	0.000128	0.00102	CcSEcCtD
Omeprazole—Dysgeusia—Methotrexate—bone cancer	0.000128	0.00101	CcSEcCtD
Omeprazole—Connective tissue disorder—Doxorubicin—bone cancer	0.000128	0.00101	CcSEcCtD
Omeprazole—Urethral disorder—Doxorubicin—bone cancer	0.000127	0.00101	CcSEcCtD
Omeprazole—CYP1B1—Metapathway biotransformation—CYP3A4—bone cancer	0.000127	0.00178	CbGpPWpGaD
Omeprazole—Immune system disorder—Epirubicin—bone cancer	0.000127	0.00101	CcSEcCtD
Omeprazole—Mediastinal disorder—Epirubicin—bone cancer	0.000127	0.001	CcSEcCtD
Omeprazole—Back pain—Methotrexate—bone cancer	0.000126	0.001	CcSEcCtD
Omeprazole—Chills—Epirubicin—bone cancer	0.000126	0.000999	CcSEcCtD
Omeprazole—Visual impairment—Doxorubicin—bone cancer	0.000125	0.000993	CcSEcCtD
Omeprazole—Alopecia—Epirubicin—bone cancer	0.000124	0.000984	CcSEcCtD
Omeprazole—Vomiting—Cisplatin—bone cancer	0.000124	0.00098	CcSEcCtD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000123	0.00172	CbGpPWpGaD
Omeprazole—Vision blurred—Methotrexate—bone cancer	0.000123	0.000976	CcSEcCtD
Omeprazole—Mental disorder—Epirubicin—bone cancer	0.000123	0.000976	CcSEcCtD
Omeprazole—Erythema multiforme—Doxorubicin—bone cancer	0.000123	0.000974	CcSEcCtD
Omeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000123	0.00172	CbGpPWpGaD
Omeprazole—Rash—Cisplatin—bone cancer	0.000123	0.000972	CcSEcCtD
Omeprazole—Dermatitis—Cisplatin—bone cancer	0.000122	0.000971	CcSEcCtD
Omeprazole—Malnutrition—Epirubicin—bone cancer	0.000122	0.00097	CcSEcCtD
Omeprazole—Eye disorder—Doxorubicin—bone cancer	0.000121	0.000963	CcSEcCtD
Omeprazole—CYP11A1—Metabolism—NDUFA12—bone cancer	0.000121	0.0017	CbGpPWpGaD
Omeprazole—Ill-defined disorder—Methotrexate—bone cancer	0.000121	0.000961	CcSEcCtD
Omeprazole—Tinnitus—Doxorubicin—bone cancer	0.000121	0.000961	CcSEcCtD
Omeprazole—Anaemia—Methotrexate—bone cancer	0.000121	0.000958	CcSEcCtD
Omeprazole—Flushing—Doxorubicin—bone cancer	0.000121	0.000956	CcSEcCtD
Omeprazole—Flatulence—Epirubicin—bone cancer	0.000121	0.000955	CcSEcCtD
Omeprazole—Tension—Epirubicin—bone cancer	0.00012	0.000951	CcSEcCtD
Omeprazole—Dysgeusia—Epirubicin—bone cancer	0.00012	0.000949	CcSEcCtD
Omeprazole—Nervousness—Epirubicin—bone cancer	0.000119	0.000942	CcSEcCtD
Omeprazole—Back pain—Epirubicin—bone cancer	0.000118	0.000938	CcSEcCtD
Omeprazole—Malaise—Methotrexate—bone cancer	0.000118	0.000934	CcSEcCtD
Omeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000118	0.00165	CbGpPWpGaD
Omeprazole—Muscle spasms—Epirubicin—bone cancer	0.000118	0.000932	CcSEcCtD
Omeprazole—Immune system disorder—Doxorubicin—bone cancer	0.000117	0.000931	CcSEcCtD
Omeprazole—Vertigo—Methotrexate—bone cancer	0.000117	0.000931	CcSEcCtD
Omeprazole—Mediastinal disorder—Doxorubicin—bone cancer	0.000117	0.000929	CcSEcCtD
Omeprazole—Leukopenia—Methotrexate—bone cancer	0.000117	0.000927	CcSEcCtD
Omeprazole—Chills—Doxorubicin—bone cancer	0.000117	0.000925	CcSEcCtD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000117	0.00163	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000117	0.00163	CbGpPWpGaD
Omeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000116	0.00163	CbGpPWpGaD
Omeprazole—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000116	0.00163	CbGpPWpGaD
Omeprazole—Nausea—Cisplatin—bone cancer	0.000115	0.000915	CcSEcCtD
Omeprazole—Vision blurred—Epirubicin—bone cancer	0.000115	0.000914	CcSEcCtD
Omeprazole—Alopecia—Doxorubicin—bone cancer	0.000115	0.000911	CcSEcCtD
Omeprazole—Cough—Methotrexate—bone cancer	0.000114	0.000904	CcSEcCtD
Omeprazole—Mental disorder—Doxorubicin—bone cancer	0.000114	0.000903	CcSEcCtD
Omeprazole—Ill-defined disorder—Epirubicin—bone cancer	0.000113	0.0009	CcSEcCtD
Omeprazole—Malnutrition—Doxorubicin—bone cancer	0.000113	0.000897	CcSEcCtD
Omeprazole—Anaemia—Epirubicin—bone cancer	0.000113	0.000896	CcSEcCtD
Omeprazole—ABCC3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000113	0.00158	CbGpPWpGaD
Omeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000113	0.00158	CbGpPWpGaD
Omeprazole—Agitation—Epirubicin—bone cancer	0.000112	0.000891	CcSEcCtD
Omeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000112	0.00156	CbGpPWpGaD
Omeprazole—Flatulence—Doxorubicin—bone cancer	0.000111	0.000884	CcSEcCtD
Omeprazole—Arthralgia—Methotrexate—bone cancer	0.000111	0.000882	CcSEcCtD
Omeprazole—Myalgia—Methotrexate—bone cancer	0.000111	0.000882	CcSEcCtD
Omeprazole—Chest pain—Methotrexate—bone cancer	0.000111	0.000882	CcSEcCtD
Omeprazole—Tension—Doxorubicin—bone cancer	0.000111	0.00088	CcSEcCtD
Omeprazole—Dysgeusia—Doxorubicin—bone cancer	0.000111	0.000879	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00011	0.000876	CcSEcCtD
Omeprazole—CYP1B1—Biological oxidations—GSTP1—bone cancer	0.00011	0.00155	CbGpPWpGaD
Omeprazole—Malaise—Epirubicin—bone cancer	0.00011	0.000874	CcSEcCtD
Omeprazole—Discomfort—Methotrexate—bone cancer	0.00011	0.000871	CcSEcCtD
Omeprazole—Nervousness—Doxorubicin—bone cancer	0.00011	0.000871	CcSEcCtD
Omeprazole—Vertigo—Epirubicin—bone cancer	0.00011	0.000871	CcSEcCtD
Omeprazole—Leukopenia—Epirubicin—bone cancer	0.000109	0.000868	CcSEcCtD
Omeprazole—Back pain—Doxorubicin—bone cancer	0.000109	0.000868	CcSEcCtD
Omeprazole—CYP1B1—Metapathway biotransformation—GSTP1—bone cancer	0.000109	0.00153	CbGpPWpGaD
Omeprazole—Muscle spasms—Doxorubicin—bone cancer	0.000109	0.000863	CcSEcCtD
Omeprazole—Palpitations—Epirubicin—bone cancer	0.000108	0.000857	CcSEcCtD
Omeprazole—Confusional state—Methotrexate—bone cancer	0.000108	0.000853	CcSEcCtD
Omeprazole—Cough—Epirubicin—bone cancer	0.000107	0.000846	CcSEcCtD
Omeprazole—Anaphylactic shock—Methotrexate—bone cancer	0.000107	0.000846	CcSEcCtD
Omeprazole—Vision blurred—Doxorubicin—bone cancer	0.000107	0.000845	CcSEcCtD
Omeprazole—Infection—Methotrexate—bone cancer	0.000106	0.00084	CcSEcCtD
Omeprazole—Hypertension—Epirubicin—bone cancer	0.000106	0.000837	CcSEcCtD
Omeprazole—CYP2C18—Metabolism—NDUFA12—bone cancer	0.000105	0.00147	CbGpPWpGaD
Omeprazole—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000105	0.00147	CbGpPWpGaD
Omeprazole—Ill-defined disorder—Doxorubicin—bone cancer	0.000105	0.000832	CcSEcCtD
Omeprazole—Nervous system disorder—Methotrexate—bone cancer	0.000105	0.000829	CcSEcCtD
Omeprazole—Anaemia—Doxorubicin—bone cancer	0.000105	0.000829	CcSEcCtD
Omeprazole—Thrombocytopenia—Methotrexate—bone cancer	0.000104	0.000828	CcSEcCtD
Omeprazole—Arthralgia—Epirubicin—bone cancer	0.000104	0.000825	CcSEcCtD
Omeprazole—Myalgia—Epirubicin—bone cancer	0.000104	0.000825	CcSEcCtD
Omeprazole—Chest pain—Epirubicin—bone cancer	0.000104	0.000825	CcSEcCtD
Omeprazole—Agitation—Doxorubicin—bone cancer	0.000104	0.000824	CcSEcCtD
Omeprazole—Anxiety—Epirubicin—bone cancer	0.000104	0.000823	CcSEcCtD
Omeprazole—Skin disorder—Methotrexate—bone cancer	0.000104	0.000821	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000103	0.00082	CcSEcCtD
Omeprazole—Hyperhidrosis—Methotrexate—bone cancer	0.000103	0.000817	CcSEcCtD
Omeprazole—Discomfort—Epirubicin—bone cancer	0.000103	0.000816	CcSEcCtD
Omeprazole—ABCC3—Metabolism—NDUFA12—bone cancer	0.000102	0.00143	CbGpPWpGaD
Omeprazole—Malaise—Doxorubicin—bone cancer	0.000102	0.000809	CcSEcCtD
Omeprazole—Dry mouth—Epirubicin—bone cancer	0.000102	0.000807	CcSEcCtD
Omeprazole—Vertigo—Doxorubicin—bone cancer	0.000102	0.000806	CcSEcCtD
Omeprazole—Anorexia—Methotrexate—bone cancer	0.000102	0.000806	CcSEcCtD
Omeprazole—Leukopenia—Doxorubicin—bone cancer	0.000101	0.000803	CcSEcCtD
Omeprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000101	0.00142	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000101	0.00142	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000101	0.00141	CbGpPWpGaD
Omeprazole—Confusional state—Epirubicin—bone cancer	0.000101	0.000798	CcSEcCtD
Omeprazole—CYP11A1—Metabolism—NT5C3A—bone cancer	0.000101	0.00141	CbGpPWpGaD
Omeprazole—Palpitations—Doxorubicin—bone cancer	0.0001	0.000793	CcSEcCtD
Omeprazole—Anaphylactic shock—Epirubicin—bone cancer	9.98e-05	0.000791	CcSEcCtD
Omeprazole—Infection—Epirubicin—bone cancer	9.92e-05	0.000786	CcSEcCtD
Omeprazole—Cough—Doxorubicin—bone cancer	9.87e-05	0.000783	CcSEcCtD
Omeprazole—Shock—Epirubicin—bone cancer	9.82e-05	0.000779	CcSEcCtD
Omeprazole—Nervous system disorder—Epirubicin—bone cancer	9.79e-05	0.000776	CcSEcCtD
Omeprazole—Thrombocytopenia—Epirubicin—bone cancer	9.77e-05	0.000775	CcSEcCtD
Omeprazole—Hypertension—Doxorubicin—bone cancer	9.77e-05	0.000775	CcSEcCtD
Omeprazole—Tachycardia—Epirubicin—bone cancer	9.74e-05	0.000772	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Methotrexate—bone cancer	9.72e-05	0.00077	CcSEcCtD
Omeprazole—Skin disorder—Epirubicin—bone cancer	9.69e-05	0.000769	CcSEcCtD
Omeprazole—Hyperhidrosis—Epirubicin—bone cancer	9.65e-05	0.000765	CcSEcCtD
Omeprazole—Insomnia—Methotrexate—bone cancer	9.65e-05	0.000765	CcSEcCtD
Omeprazole—Arthralgia—Doxorubicin—bone cancer	9.63e-05	0.000764	CcSEcCtD
Omeprazole—Myalgia—Doxorubicin—bone cancer	9.63e-05	0.000764	CcSEcCtD
Omeprazole—Chest pain—Doxorubicin—bone cancer	9.63e-05	0.000764	CcSEcCtD
Omeprazole—Anxiety—Doxorubicin—bone cancer	9.6e-05	0.000761	CcSEcCtD
Omeprazole—Paraesthesia—Methotrexate—bone cancer	9.58e-05	0.000759	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	9.57e-05	0.000759	CcSEcCtD
Omeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.55e-05	0.00134	CbGpPWpGaD
Omeprazole—Discomfort—Doxorubicin—bone cancer	9.52e-05	0.000755	CcSEcCtD
Omeprazole—Anorexia—Epirubicin—bone cancer	9.51e-05	0.000754	CcSEcCtD
Omeprazole—Dyspnoea—Methotrexate—bone cancer	9.51e-05	0.000754	CcSEcCtD
Omeprazole—Somnolence—Methotrexate—bone cancer	9.48e-05	0.000752	CcSEcCtD
Omeprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	9.47e-05	0.00133	CbGpPWpGaD
Omeprazole—Dry mouth—Doxorubicin—bone cancer	9.42e-05	0.000747	CcSEcCtD
Omeprazole—Dyspepsia—Methotrexate—bone cancer	9.39e-05	0.000744	CcSEcCtD
Omeprazole—Confusional state—Doxorubicin—bone cancer	9.31e-05	0.000738	CcSEcCtD
Omeprazole—Decreased appetite—Methotrexate—bone cancer	9.27e-05	0.000735	CcSEcCtD
Omeprazole—Anaphylactic shock—Doxorubicin—bone cancer	9.23e-05	0.000732	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Methotrexate—bone cancer	9.21e-05	0.00073	CcSEcCtD
Omeprazole—Fatigue—Methotrexate—bone cancer	9.19e-05	0.000729	CcSEcCtD
Omeprazole—Infection—Doxorubicin—bone cancer	9.17e-05	0.000727	CcSEcCtD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.13e-05	0.00128	CbGpPWpGaD
Omeprazole—Pain—Methotrexate—bone cancer	9.12e-05	0.000723	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Epirubicin—bone cancer	9.09e-05	0.000721	CcSEcCtD
Omeprazole—Shock—Doxorubicin—bone cancer	9.09e-05	0.00072	CcSEcCtD
Omeprazole—Nervous system disorder—Doxorubicin—bone cancer	9.06e-05	0.000718	CcSEcCtD
Omeprazole—Thrombocytopenia—Doxorubicin—bone cancer	9.04e-05	0.000717	CcSEcCtD
Omeprazole—Insomnia—Epirubicin—bone cancer	9.03e-05	0.000716	CcSEcCtD
Omeprazole—Tachycardia—Doxorubicin—bone cancer	9.01e-05	0.000715	CcSEcCtD
Omeprazole—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.01e-05	0.00126	CbGpPWpGaD
Omeprazole—Skin disorder—Doxorubicin—bone cancer	8.97e-05	0.000711	CcSEcCtD
Omeprazole—Paraesthesia—Epirubicin—bone cancer	8.96e-05	0.000711	CcSEcCtD
Omeprazole—Hyperhidrosis—Doxorubicin—bone cancer	8.93e-05	0.000708	CcSEcCtD
Omeprazole—Dyspnoea—Epirubicin—bone cancer	8.9e-05	0.000705	CcSEcCtD
Omeprazole—Somnolence—Epirubicin—bone cancer	8.87e-05	0.000703	CcSEcCtD
Omeprazole—Anorexia—Doxorubicin—bone cancer	8.8e-05	0.000698	CcSEcCtD
Omeprazole—Feeling abnormal—Methotrexate—bone cancer	8.79e-05	0.000697	CcSEcCtD
Omeprazole—Dyspepsia—Epirubicin—bone cancer	8.79e-05	0.000697	CcSEcCtD
Omeprazole—Gastrointestinal pain—Methotrexate—bone cancer	8.72e-05	0.000691	CcSEcCtD
Omeprazole—CYP2C18—Metabolism—NT5C3A—bone cancer	8.7e-05	0.00122	CbGpPWpGaD
Omeprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	8.68e-05	0.00122	CbGpPWpGaD
Omeprazole—Decreased appetite—Epirubicin—bone cancer	8.68e-05	0.000688	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Epirubicin—bone cancer	8.62e-05	0.000683	CcSEcCtD
Omeprazole—Fatigue—Epirubicin—bone cancer	8.6e-05	0.000682	CcSEcCtD
Omeprazole—Constipation—Epirubicin—bone cancer	8.53e-05	0.000677	CcSEcCtD
Omeprazole—Pain—Epirubicin—bone cancer	8.53e-05	0.000677	CcSEcCtD
Omeprazole—Urticaria—Methotrexate—bone cancer	8.47e-05	0.000672	CcSEcCtD
Omeprazole—ABCC3—Metabolism—NT5C3A—bone cancer	8.47e-05	0.00119	CbGpPWpGaD
Omeprazole—Body temperature increased—Methotrexate—bone cancer	8.43e-05	0.000668	CcSEcCtD
Omeprazole—Abdominal pain—Methotrexate—bone cancer	8.43e-05	0.000668	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.41e-05	0.000667	CcSEcCtD
Omeprazole—Insomnia—Doxorubicin—bone cancer	8.35e-05	0.000662	CcSEcCtD
Omeprazole—Paraesthesia—Doxorubicin—bone cancer	8.29e-05	0.000657	CcSEcCtD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	8.29e-05	0.00116	CbGpPWpGaD
Omeprazole—Dyspnoea—Doxorubicin—bone cancer	8.23e-05	0.000653	CcSEcCtD
Omeprazole—Feeling abnormal—Epirubicin—bone cancer	8.22e-05	0.000652	CcSEcCtD
Omeprazole—Somnolence—Doxorubicin—bone cancer	8.21e-05	0.000651	CcSEcCtD
Omeprazole—Gastrointestinal pain—Epirubicin—bone cancer	8.16e-05	0.000647	CcSEcCtD
Omeprazole—Dyspepsia—Doxorubicin—bone cancer	8.13e-05	0.000645	CcSEcCtD
Omeprazole—Decreased appetite—Doxorubicin—bone cancer	8.03e-05	0.000636	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Doxorubicin—bone cancer	7.97e-05	0.000632	CcSEcCtD
Omeprazole—Fatigue—Doxorubicin—bone cancer	7.96e-05	0.000631	CcSEcCtD
Omeprazole—CYP1A1—Biological oxidations—CYP3A4—bone cancer	7.95e-05	0.00111	CbGpPWpGaD
Omeprazole—Urticaria—Epirubicin—bone cancer	7.93e-05	0.000629	CcSEcCtD
Omeprazole—Pain—Doxorubicin—bone cancer	7.9e-05	0.000626	CcSEcCtD
Omeprazole—Constipation—Doxorubicin—bone cancer	7.9e-05	0.000626	CcSEcCtD
Omeprazole—Body temperature increased—Epirubicin—bone cancer	7.89e-05	0.000626	CcSEcCtD
Omeprazole—Abdominal pain—Epirubicin—bone cancer	7.89e-05	0.000626	CcSEcCtD
Omeprazole—Hypersensitivity—Methotrexate—bone cancer	7.86e-05	0.000623	CcSEcCtD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.85e-05	0.0011	CbGpPWpGaD
Omeprazole—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	7.85e-05	0.0011	CbGpPWpGaD
Omeprazole—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.78e-05	0.00109	CbGpPWpGaD
Omeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.75e-05	0.00108	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—NDUFA12—bone cancer	7.74e-05	0.00108	CbGpPWpGaD
Omeprazole—Asthenia—Methotrexate—bone cancer	7.65e-05	0.000607	CcSEcCtD
Omeprazole—Feeling abnormal—Doxorubicin—bone cancer	7.61e-05	0.000603	CcSEcCtD
Omeprazole—Gastrointestinal pain—Doxorubicin—bone cancer	7.55e-05	0.000599	CcSEcCtD
Omeprazole—Pruritus—Methotrexate—bone cancer	7.55e-05	0.000598	CcSEcCtD
Omeprazole—CYP1A2—Phase II conjugation—GSTP1—bone cancer	7.41e-05	0.00104	CbGpPWpGaD
Omeprazole—Hypersensitivity—Epirubicin—bone cancer	7.35e-05	0.000583	CcSEcCtD
Omeprazole—Urticaria—Doxorubicin—bone cancer	7.34e-05	0.000582	CcSEcCtD
Omeprazole—Body temperature increased—Doxorubicin—bone cancer	7.3e-05	0.000579	CcSEcCtD
Omeprazole—Abdominal pain—Doxorubicin—bone cancer	7.3e-05	0.000579	CcSEcCtD
Omeprazole—Diarrhoea—Methotrexate—bone cancer	7.3e-05	0.000579	CcSEcCtD
Omeprazole—CYP2C8—Biological oxidations—CYP3A4—bone cancer	7.29e-05	0.00102	CbGpPWpGaD
Omeprazole—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	7.19e-05	0.00101	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.18e-05	0.001	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.18e-05	0.001	CbGpPWpGaD
Omeprazole—Asthenia—Epirubicin—bone cancer	7.16e-05	0.000568	CcSEcCtD
Omeprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	7.07e-05	0.000989	CbGpPWpGaD
Omeprazole—Pruritus—Epirubicin—bone cancer	7.06e-05	0.00056	CcSEcCtD
Omeprazole—Dizziness—Methotrexate—bone cancer	7.05e-05	0.000559	CcSEcCtD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.05e-05	0.000986	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—NDUFA12—bone cancer	7.04e-05	0.000986	CbGpPWpGaD
Omeprazole—Diarrhoea—Epirubicin—bone cancer	6.83e-05	0.000541	CcSEcCtD
Omeprazole—Hypersensitivity—Doxorubicin—bone cancer	6.8e-05	0.000539	CcSEcCtD
Omeprazole—CYP1A1—Biological oxidations—GSTP1—bone cancer	6.8e-05	0.000952	CbGpPWpGaD
Omeprazole—Vomiting—Methotrexate—bone cancer	6.78e-05	0.000538	CcSEcCtD
Omeprazole—Rash—Methotrexate—bone cancer	6.72e-05	0.000533	CcSEcCtD
Omeprazole—Dermatitis—Methotrexate—bone cancer	6.72e-05	0.000533	CcSEcCtD
Omeprazole—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	6.71e-05	0.000939	CbGpPWpGaD
Omeprazole—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.7e-05	0.000937	CbGpPWpGaD
Omeprazole—Headache—Methotrexate—bone cancer	6.68e-05	0.00053	CcSEcCtD
Omeprazole—Asthenia—Doxorubicin—bone cancer	6.63e-05	0.000525	CcSEcCtD
Omeprazole—Dizziness—Epirubicin—bone cancer	6.6e-05	0.000523	CcSEcCtD
Omeprazole—Pruritus—Doxorubicin—bone cancer	6.53e-05	0.000518	CcSEcCtD
Omeprazole—CYP2C19—Biological oxidations—CYP3A4—bone cancer	6.51e-05	0.000911	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.45e-05	0.000904	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	6.42e-05	0.000899	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.42e-05	0.000898	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—NT5C3A—bone cancer	6.42e-05	0.000898	CbGpPWpGaD
Omeprazole—Vomiting—Epirubicin—bone cancer	6.35e-05	0.000503	CcSEcCtD
Omeprazole—Nausea—Methotrexate—bone cancer	6.33e-05	0.000502	CcSEcCtD
Omeprazole—Diarrhoea—Doxorubicin—bone cancer	6.32e-05	0.000501	CcSEcCtD
Omeprazole—Rash—Epirubicin—bone cancer	6.29e-05	0.000499	CcSEcCtD
Omeprazole—Dermatitis—Epirubicin—bone cancer	6.29e-05	0.000498	CcSEcCtD
Omeprazole—Headache—Epirubicin—bone cancer	6.25e-05	0.000496	CcSEcCtD
Omeprazole—CYP2C8—Biological oxidations—GSTP1—bone cancer	6.24e-05	0.000873	CbGpPWpGaD
Omeprazole—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	6.15e-05	0.000861	CbGpPWpGaD
Omeprazole—Dizziness—Doxorubicin—bone cancer	6.11e-05	0.000484	CcSEcCtD
Omeprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.04e-05	0.000845	CbGpPWpGaD
Omeprazole—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.99e-05	0.000838	CbGpPWpGaD
Omeprazole—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.94e-05	0.000831	CbGpPWpGaD
Omeprazole—Nausea—Epirubicin—bone cancer	5.93e-05	0.00047	CcSEcCtD
Omeprazole—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.9e-05	0.000827	CbGpPWpGaD
Omeprazole—Vomiting—Doxorubicin—bone cancer	5.87e-05	0.000466	CcSEcCtD
Omeprazole—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.85e-05	0.000819	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.84e-05	0.000818	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—NT5C3A—bone cancer	5.84e-05	0.000817	CbGpPWpGaD
Omeprazole—Rash—Doxorubicin—bone cancer	5.82e-05	0.000462	CcSEcCtD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.82e-05	0.000815	CbGpPWpGaD
Omeprazole—Dermatitis—Doxorubicin—bone cancer	5.82e-05	0.000461	CcSEcCtD
Omeprazole—Headache—Doxorubicin—bone cancer	5.79e-05	0.000459	CcSEcCtD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.76e-05	0.000807	CbGpPWpGaD
Omeprazole—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.57e-05	0.000779	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.49e-05	0.000769	CbGpPWpGaD
Omeprazole—Nausea—Doxorubicin—bone cancer	5.49e-05	0.000435	CcSEcCtD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.46e-05	0.000765	CbGpPWpGaD
Omeprazole—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.17e-05	0.000723	CbGpPWpGaD
Omeprazole—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.12e-05	0.000717	CbGpPWpGaD
Omeprazole—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.08e-05	0.000711	CbGpPWpGaD
Omeprazole—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.07e-05	0.00071	CbGpPWpGaD
Omeprazole—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.05e-05	0.000707	CbGpPWpGaD
Omeprazole—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.01e-05	0.000701	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5e-05	0.0007	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.88e-05	0.000684	CbGpPWpGaD
Omeprazole—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.87e-05	0.000682	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—NDUFA12—bone cancer	4.77e-05	0.000667	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.58e-05	0.000641	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.58e-05	0.000641	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—ENO2—bone cancer	4.41e-05	0.000617	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—NDUFA12—bone cancer	4.37e-05	0.000612	CbGpPWpGaD
Omeprazole—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.34e-05	0.000607	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.28e-05	0.000599	CbGpPWpGaD
Omeprazole—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.2e-05	0.000589	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—DHFR—bone cancer	4.09e-05	0.000572	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—NT5C3A—bone cancer	3.95e-05	0.000553	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—NDUFA12—bone cancer	3.9e-05	0.000546	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—GNA11—bone cancer	3.82e-05	0.000535	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—ENO2—bone cancer	3.81e-05	0.000534	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—NDUFA12—bone cancer	3.81e-05	0.000533	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—ENO2—bone cancer	3.71e-05	0.000519	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.62e-05	0.000507	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—NT5C3A—bone cancer	3.62e-05	0.000507	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—NDUFA12—bone cancer	3.59e-05	0.000502	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—NDUFA12—bone cancer	3.56e-05	0.000498	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—DHFR—bone cancer	3.54e-05	0.000495	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—CYP3A4—bone cancer	3.46e-05	0.000485	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.45e-05	0.000482	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—DHFR—bone cancer	3.44e-05	0.000482	CbGpPWpGaD
Omeprazole—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.35e-05	0.000469	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—GNA11—bone cancer	3.3e-05	0.000463	CbGpPWpGaD
Omeprazole—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.3e-05	0.000462	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—NT5C3A—bone cancer	3.23e-05	0.000453	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—GNA11—bone cancer	3.21e-05	0.00045	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—NT5C3A—bone cancer	3.16e-05	0.000442	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—NDUFA12—bone cancer	3.04e-05	0.000426	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—CYP3A4—bone cancer	3e-05	0.000419	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—NT5C3A—bone cancer	2.97e-05	0.000416	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—GSTP1—bone cancer	2.96e-05	0.000415	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—NT5C3A—bone cancer	2.95e-05	0.000413	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—CYP3A4—bone cancer	2.91e-05	0.000408	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.9e-05	0.000406	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—ENO2—bone cancer	2.81e-05	0.000393	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.69e-05	0.000376	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—DHFR—bone cancer	2.61e-05	0.000365	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.59e-05	0.000362	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—GSTP1—bone cancer	2.56e-05	0.000359	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—ENO2—bone cancer	2.56e-05	0.000358	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—NT5C3A—bone cancer	2.52e-05	0.000353	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—GSTP1—bone cancer	2.49e-05	0.000349	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—GNA11—bone cancer	2.44e-05	0.000341	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—DHFR—bone cancer	2.37e-05	0.000332	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—NDUFA12—bone cancer	2.35e-05	0.000328	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.33e-05	0.000327	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—GNA11—bone cancer	2.22e-05	0.00031	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—CYP3A4—bone cancer	2.21e-05	0.000309	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.2e-05	0.000308	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—CYP3A4—bone cancer	2.01e-05	0.000281	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—NT5C3A—bone cancer	1.94e-05	0.000272	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—GSTP1—bone cancer	1.89e-05	0.000264	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.84e-05	0.000257	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—ENO2—bone cancer	1.73e-05	0.000242	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—GSTP1—bone cancer	1.72e-05	0.000241	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—DHFR—bone cancer	1.61e-05	0.000225	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—ENO2—bone cancer	1.59e-05	0.000222	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.54e-05	0.000216	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—PTGS2—bone cancer	1.53e-05	0.000215	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—GNA11—bone cancer	1.5e-05	0.00021	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—DHFR—bone cancer	1.47e-05	0.000206	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—ENO2—bone cancer	1.42e-05	0.000198	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—ENO2—bone cancer	1.38e-05	0.000194	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—GNA11—bone cancer	1.38e-05	0.000193	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—CYP3A4—bone cancer	1.36e-05	0.00019	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.000189	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—PTGS2—bone cancer	1.33e-05	0.000186	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—DHFR—bone cancer	1.31e-05	0.000184	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—ENO2—bone cancer	1.3e-05	0.000182	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—PTGS2—bone cancer	1.29e-05	0.000181	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—ENO2—bone cancer	1.29e-05	0.000181	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—DHFR—bone cancer	1.28e-05	0.00018	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000175	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.24e-05	0.000174	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—GNA11—bone cancer	1.23e-05	0.000172	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—DHFR—bone cancer	1.21e-05	0.000169	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—GNA11—bone cancer	1.2e-05	0.000168	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—DHFR—bone cancer	1.2e-05	0.000168	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—GSTP1—bone cancer	1.16e-05	0.000163	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—GNA11—bone cancer	1.13e-05	0.000158	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—GNA11—bone cancer	1.12e-05	0.000157	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000156	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.11e-05	0.000155	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—ENO2—bone cancer	1.1e-05	0.000154	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—CYP3A4—bone cancer	1.09e-05	0.000152	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—GSTP1—bone cancer	1.07e-05	0.000149	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000143	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—DHFR—bone cancer	1.02e-05	0.000143	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000142	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.01e-05	0.000141	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—PTGS2—bone cancer	9.79e-06	0.000137	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—GNA11—bone cancer	9.57e-06	0.000134	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—GSTP1—bone cancer	9.52e-06	0.000133	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—GSTP1—bone cancer	9.29e-06	0.00013	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—PTGS2—bone cancer	8.9e-06	0.000125	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—GSTP1—bone cancer	8.76e-06	0.000123	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—GSTP1—bone cancer	8.68e-06	0.000122	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—CYP3A4—bone cancer	8.67e-06	0.000121	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.63e-06	0.000121	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—ENO2—bone cancer	8.52e-06	0.000119	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—DHFR—bone cancer	7.9e-06	0.000111	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—GSTP1—bone cancer	7.42e-06	0.000104	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—GNA11—bone cancer	7.38e-06	0.000103	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—PTGS2—bone cancer	6.03e-06	8.44e-05	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—GSTP1—bone cancer	5.73e-06	8.01e-05	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—PTGS2—bone cancer	5.53e-06	7.74e-05	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—PTGS2—bone cancer	4.93e-06	6.91e-05	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—PTGS2—bone cancer	4.81e-06	6.74e-05	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—PTGS2—bone cancer	4.54e-06	6.35e-05	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—PTGS2—bone cancer	4.5e-06	6.3e-05	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—PTGS2—bone cancer	3.84e-06	5.38e-05	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—PTGS2—bone cancer	2.97e-06	4.15e-05	CbGpPWpGaD
